EIF4EBP1 and glomerular disorder: Furthermore, we found targeting 4E-BP1 activation with the RNA interference of 4E-BP1 or pharmacologic rapamycin (inhibitor of mTORC1, blocking mTORC1-dependent phosphorylation of its substrate 4E-BP1) treatment could inhibit podocyte cell cycle re-entry and suppress the podocyte injury and loss induced by adriamycin, providing a new potential target for ameliorating podocyte injury in glomerular disorders.